{"name":"HELSINN HLTHCARE","slug":"helsinn-hlthcare","ticker":"","exchange":"","domain":"helsinnhlthcare.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2014-01-01","label":"Akynzeo first approved","drug":"Akynzeo","drugSlug":"netupitant","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Akynzeo first approved","drug":"Akynzeo","drugSlug":"fosnetupitant","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Truseltiq first approved","drug":"Truseltiq","drugSlug":"infigratinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Akynzeo","genericName":"FOSNETUPITANT","slug":"fosnetupitant","indication":"Chemotherapy-induced nausea and vomiting","status":"marketed"},{"name":"Akynzeo","genericName":"NETUPITANT","slug":"netupitant","indication":"Chemotherapy-induced nausea and vomiting","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Truseltiq","genericName":"INFIGRATINIB","slug":"infigratinib","indication":"Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion","status":"marketed"}]}],"pipeline":[{"name":"Akynzeo","genericName":"FOSNETUPITANT","slug":"fosnetupitant","phase":"marketed","mechanism":"Akynzeo works by blocking the action of substance-P, a natural substance in the body that triggers nausea and vomiting.","indications":["Chemotherapy-induced nausea and vomiting"],"catalyst":""},{"name":"Akynzeo","genericName":"NETUPITANT","slug":"netupitant","phase":"marketed","mechanism":"Akynzeo works by blocking the substance P/neurokinin-1 receptor to prevent nausea and vomiting caused by chemotherapy.","indications":["Chemotherapy-induced nausea and vomiting"],"catalyst":""},{"name":"Truseltiq","genericName":"INFIGRATINIB","slug":"infigratinib","phase":"marketed","mechanism":"Fibroblast growth factor receptor 2","indications":["Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}